Over the last couple of months we’ve been busy planning and working on the UK launch of a unique and world-beating medical device.
The Swiss healthtech start-up Aktiia has beaten the likes of Samsung, Apple and Fitbit to produce the world’s first clinically validated medical device that automatically and accurately measures a user’s blood pressure from the wrist.
Fifteen years in the making, the Aktiia bracelet is elegant, practical and lightweight – qualities you’d expect from a country steeped in the history of watch making.
The bracelet – which has gained regulatory approval for sale as a medical device across Europe – gathers blood pressure data every 90 minutes throughout the day and night. The information is automatically sent to a linked phone where it can be viewed by the user and their doctor.
Launched during the peak of the second wave of the Covid-19 pandemic, we knew we had our work cut out to secure the sort of coverage such a revolutionary device warranted.
Armed with a brief of generating stories in both top tier and trade titles, our campaign kicked off with an interview with the Financial Time’s technology site, Sifted – quickly followed by another supportive piece in Forbes.
With a need for health professionals to hear about the launch, medical titles were also high on Aktiia’s wish list. We more than met their expectations, with stories running in Cardiac Rhythm News and Cardio Vascular News.
In addition, key medtech trade publications also published stories including Medtech News, MobiHealth News, Medical Device Network, Health Tech News, Health Tech World, UK Biotech and Medical Device Network.
And to cap off the campaign, we also persuaded a number of popular consumer tech sites to cover Aktiia’s news including Wearable, Gadgets & Wearables, Medgadget and Mighty Gadget.
Not a bad result for a previously unknown and untalked about Swiss start-up.
